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I nflammatory bowel diseases (IBD), including the 2 main subtypes Crohn's disease (CD) and ulcerative colitis (UC), are characterized by a heterogeneous clinical manifestation and a chronic relapsing-remitting course. 1 Two important novel insights prompt the use of patientreported outcome measures (PROMs) for optimal management of patients with IBD. First, to prevent disease progression and improve the long-term disease outcome, including complications, hospitalization, and surgery, management of IBD is shifting from mere control of symptoms toward tight control of mucosal inflammation and early intervention in case of a relapse. 2 Mucosal inflammation, further referred to as disease activity, is ideally assessed by endoscopy; however, this examination is too invasive and costly for frequent evaluation. Therefore, noninvasive biomarkers, such as C-reactive protein (CRP) and fecal calprotectin (FCP), or clinicianreported activity indices, such as the Harvey Bradshaw Index (HBI), Crohn's Disease Activity Index (CDAI), or Simple Clinical Colitis Activity Index (SCCAI), are frequently used for monitoring of disease activity over time. As an alternative, PROMs (ie, incorporated in telemedicine systems) could assist health care professionals to implement a tight control strategy in a setting of an increasing IBD incidence with limited health care resources. 3, 4 Secondly, the focus of health care is transitioning from volume-based toward value-based systems, in which patient outcomes are evaluated relative to cost of care. 5, 6 Insurance companies, governments, and patient organizations demand registration of PROMs as efficacy endpoints of interventions in routine care. In addition, the use of patients' perspectives on the effectiveness of therapies in clinical trials is strongly recommended by the Food and Drug Administration (FDA). 5, 7, 8 The definition of a PROM is any report of the status of a patient's health condition that comes directly from the patient, without interpretation of the patient's response by a clinician or anyone else and without laboratory assessments. 8 The FDA has provided guidelines on how a PROM should be developed. 8 First, item generation of a PROM should be established by focus group interviews containing a heterogeneous group of patients regarding population characteristics, condition, and treatment. Thereafter, its construct validity, criterion validity, reliability, and ability to detect change should be evaluated to finalize the instrument. 7, 8 For IBD it is important to distinguish PROMs monitoring disease activity, from PROMs evaluating patients' perspectives on such things as disease control and quality of life. Systematic evaluation of both is important to improve the long-term outcome and value of care for patients with IBD. A wide variety of PROMs for monitoring of disease activity in patients with IBD has been developed over the past 2 decades. This review provides an overview on these PROMs and evaluates their measurement properties.
Materials and Methods

Search Strategy for Identification of Studies
A structured literature search up to December 2016 was conducted using PubMed, Medline, Embase, and the Cochrane Library to identify all articles on the development or validation of PROMs measuring disease activity in patients with IBD. Both MeSH subject headings and truncated text-words including "inflammatory bowel disease," "Crohn's disease," "ulcerative colitis," "disease activity," "score," "questionnaire," "index," "measurement," "patient-reported outcome measure," "selfreported," and similar keywords were used.
Criteria for Study Selection
Two authors (M.J.d.J., R.H.) independently reviewed titles and abstracts from the search strategies and identified eligible studies. Full texts were obtained and reviewed when articles met all of the following criteria: (1) English language; (2) published in an international peer-reviewed journal; (3) assessing adult or pediatric patients with IBD (UC, CD, or both); (4) reported on patient-reported questionnaires measuring disease activity; and (5) contained data regarding diagnostic accuracy of the questionnaire compared with endoscopy, or with laboratory parameters, such as CRP, FCP, or erythrocyte sedimentation rate (ESR), or with clinicianreported disease activity questionnaires, such as the physician global assessment (PGA), CDAI, HBI, SCCAI, Pediatric Ulcerative Colitis Activity Index (PUCAI), or Mayo score (full Mayo score: stool frequency, rectal bleeding, endoscopic examination, and PGA [12-item] ; partial Mayo score: stool frequency, rectal bleeding, and PGA [9-item] ). A third reviewer was consulted to reach consensus in case of disagreement.
Data Collection
Two reviewers carried out the data extraction using a standardized data extraction form and discussed the content in case of disagreement. Characteristics of the PROMs noted included study population, language, items being measured, administration mode (paper or digital), recall-period, scoring, and cutoff values. The FDA has provided guidelines on how a PROM should be developed and which measurement properties should be evaluated. 8 First, content validity, which is defined as the extent to which an instrument measures the concept of interest. Second, construct validity, which is determined by evidence that a relationship exists with another accepted measure of disease activity. Third, criterion validity which, represents the extent to which a PROM is related to a generally accepted gold standard measure (endoscopy for IBD disease activity). In addition, when a PROM is developed for measurements over time, such as in clinical practice or clinical trials, its adequacy also depends on its reliability to yield consistent scores over time when no change is expected in disease activity. Finally, the ability of a PROM to detect differences in scores over time (responsiveness) in individuals who have changes in disease activity is important. 8 The previously mentioned measurement properties were extracted from the included articles.
The following interpretations of statistical measures used to compare (clinical, endoscopic, or biochemical) disease activity scores were applied: correlational measures (r) were interpreted as 0.10-0.29 no/negligible correlation, 0.30-0.49 low correlation, 0.50-0.69 moderate correlation, 0.70-0.89 high correlation, and 0.90-1.00 very strong correlation. For Cohen kappa (k) measure of agreement the following definitions were used: <0.4 poor, 0.4-0.6 fair/moderate, 0.6-0.8 substantial/good, and 0.8-1.0 excellent. Area under the curve values were considered as 0.5-0.7 representing poor, 0.7-0.9 moderate, and >0.9 high accuracy. A sensitivity of !80% and a specificity of !80% were considered positive indicators of the respective measurement property.
Results
Study Selection
The search strategy resulted in a total of 973 hits. Details on the selection process can be found in the flow chart ( Figure 1 ). After removing duplicates and screening articles by title and abstract, 37 studies remained for full text assessment. Twenty articles were excluded for the following reasons: the reported instrument was not patient-reported (10); the reported instrument did not assess disease activity (6) ; or the article did not provide measurement properties of the PROM (4). Finally, 17 articles were included covering the following instruments: self-administered SCCAI, 9 6-point Mayo score, 10, 11 patient-assessment of disease activity, 11 Manitoba Inflammatory Bowel Disease Index (MIBDI), 12 survey-index CDAI, 13 patient-based PUCAI, 14 patients' global assessment, 15 patient-SCCAI, 16 patient-HBI, 17 Numeric Rating Scale (NRS), 18 mobile health index (mHI), 19 patient-reported outcome derived from the Mayo score (PRO2), 20 patient-reported outcome derived from the CDAI (PRO3), 21 simple 0-10 numerical score (IBD-10), 22 patient-reported HBI, 23 patient-reported SCCAI, 23 digital self-administered SCCAI, 24, 25 and digital self-administered HBI. 25 
Study Characteristics
An overview of the study characteristics, including the reasons for PROM development, is given in Table 1 . Included studies were conducted between 1999 and 2016 with study populations varying from 46 to 566 patients. Three studies included patients with CD, 13, 17, 21 a total of 8 included patients with UC, [9] [10] [11] [14] [15] [16] 20, 24 and 6 included both CD and patients with UC. 12, 18, 19, 22, 23, 25 . Most studies included only adult patients, whereas 2 included children in their studies.
14,15
Characteristics and Measurement Properties of Patient-Reported Outcome Measures
Characteristics of patient-reported outcome measures.
Characteristics of the included patient-reported To identify the most optimal PRO score to use on an IBD diseasemonitoring app Because the main purpose of a PROM is to capture patients' perspectives, the FDA recommends patient input during instrument development. Two articles reported on patients' experiences regarding the tested PROM. 9, 18 However, only Bennebroek et al 16, 17 documented qualitative patient interviews as part of the PROM development ( Table 2) . Construct validity. Seven articles investigated the correlation between clinician-reported indices and their patient-reported version ( Table 2) . The SCCAI when selfadministered by patients showed a high correlation and substantial to good agreement when compared with the clinician-reported version. 9, 16 The individual items "daytime frequency," "night-time frequency," and "blood in stool" showed better agreement than the items on "urgency," "well-being," and "extraintestinal manifestations." 9 The self-administered SCCAI showed, however, a poor correlation with FCP levels. 23 Patient-based and clinician-based HBI scores were also compared and showed a high correlation, but moderate agreement between the 2 questionnaires. 17 Additionally, the patientreported HBI showed a poor correlation with FCP levels (Table 2 ). In children, Lee et al 14 found good agreement between the PUCAI when self-administered and when clinician-completed. Compared with the PGA, the self-administered PUCAI showed moderate agreement.
14 Both patient-and clinician-completed PUCAI scores did correlate moderately with CRP and substantially with ESR (Table 2). 14 Two articles elaborated on the correlation between an online-administered questionnaire and a paper version (Table 2 ). Both studies showed good agreement between the HBI and SCCAI filled out on paper and via a web tool. 24, 25 Five studies used subcomponents of a conventional clinical index to develop a new PROM. Three of these used the 2 patient-reported items from the Mayo score (ie, stool frequency and rectal bleeding). 10, 11, 20 These items combined showed an area under the curve of 0.80 when compared with the endoscopic modified Baron score, 20 and strong correlations with the SCCAI 10 and the full Mayo score 11 ( Table 2) . Two articles composed a new PROM using the items stool frequency, abdominal pain, and general well-being from the CDAI, 13, 21 showing moderate agreement and a relatively high correlation with the CDAI 13, 21 (Table 2 ). Six articles reported on the development and validation of a new PROM relative to conventional clinical indices and/or endoscopy (Table 2) . 11, 12, 15, 18, 19, 22 The MIBDI is a single-item self-reported question on symptom persistence in the previous 6 months. The MIBDI showed good sensitivity and modest specificity when compared with the HBI and the Powel Tuck Index. 12 Lewis et al 11 asked patients to grade their current disease activity on a 6-point Likert scale from minimal symptoms to severe symptoms and found a moderate to strong correlation compared with the full Mayo score.
Three studies reported on a single-item numerical scale to capture disease activity for routine clinical use ( Table 2 ). The IBD-10, assessing "how would you rate your CD/UC today (on a scale of 0-10)," 22 showed high correlation with the SCCAI and a moderate correlation with the HBI. Although a significant correlation was found between the IBD-10 and CRP in patients with UC, no correlation was observed between the IBD-10 and CRP in patients with CD, nor with FCP in both patients with UC and patients with CD. 22 The 11-point NRS, capturing patients' overall perception of health on a scale from 0 to 10, showed a high correlation with the CDAI; moderate correlation with the HBI; and no correlation with CRP, ESR, and FCP. 18 The latter study also tested a single-item self-reported question (yes/no) on remission of the disease and found a correlation with the CDAI and HBI, but not with CRP. 18 A third study reported on a single-item question about patient-reported disease activity during the previous 2 days on a visual analogue scale. 15 This "patient global assessment" was compared with the full Mayo score, the PUCAI score, CRP, albumin, ESR, and hemoglobin, showing correlation coefficients of 0.70, 0.67, 0.34, À0.42, 0.39, and À0.24, respectively. 15 Van Deen et al 19 developed and validated a PROM to monitor disease activity for use in mobile technologies ( Table 2 ). The mHI showed high correlation and high accuracy compared with the CDAI and the HBI for patients with CD. Also for patients with UC, the mHI showed high correlation and high accuracy compared with the partial Mayo score. 19 Criterion validity. Only 4 articles reported on validation relative to endoscopic disease activity ( Table 2 ). The patient global assessment showed a moderate correlation with endoscopic inflammation scored with Beattie grading system. 15 The single-item "patient assessment of disease activity" and the 6-point Mayo score showed high correlation with the full Mayo score. 11 Jairath et al 20 reported an area under the curve of 0.80 for the 2-item (PRO2) Mayo score compared with the Mayo endoscopic subscore. The mHI-UC showed moderate accuracy in detecting mucosal inflammation compared with the Mayo endoscopic subscore, whereas the mHI-CD showed poor accuracy identifying patients with active disease compared with the simple endoscopic score for CD.
19
Reliability. Three articles investigated this test-retest reliability ( Table 2 ). The MIBDI showed strong testretest reliability when the question was readministered after 1 week, with high correlation between the 2 MIBDI scores and good agreement for active versus inactive categorization at the 2 measurement occasions. 12 The survey-index CDAI was reliable when readministered after 2-6 weeks as shown by an intraclass correlation coefficient of 0.81. 13 For both the mHI-UC and mHI-CD, the intraclass correlation coefficient was 0.94 with a median time to second questionnaire of 22 hours. 19 Responsiveness. Ability to detect changes in disease activity (responsiveness) was tested in 5 studies (Table 2) . Timmer et al 13 reported good ability to detect change for the survey-index CDAI because the mean paired difference was different for patients whose disease activity improved or deteriorated; effect size statistics were not applied. Surti et al 18 tested responsiveness of the NRS in 10 patients with a mean between-questionnaire time of 108 days. Changes in NRS did not correlate with changes in CDAI and HBI. Van Deen et al 19 assessed sensitivity to detect change in a subset of 50 patients with a median betweenquestionnaire time of 46 days and found a significant difference in mHI score among patients who clinically improved, remained stable, or worsened. Khanna et al 21 found their PRO3 derived from the CDAI to be responsive to change. Marín-Jiménez et al 26 tested the responsiveness of online-administered SCCAI at 3 and at 6 months. The percentage of agreement with the physicians' assessment of disease activity measured with the SCCAI was 82.6% with a moderate correlation between the 2 questionnaires.
Discussion
In addition to the increasing focus on patientcentered care, tight monitoring of IBD disease activity is advocated to improve long-term disease outcome. This systematic review provides an overview on the current available PROMs for measurement of IBD disease activity based on their measurement properties. A wide variety of PROMs has been developed, but none of these meet all the criteria for PROM development as recommended by the FDA. 8 The adequacy and accuracy of a PROM extensively depend on its content and on its criterion validity. Because a PROM is aimed at the reflection of what is important to patients, evaluation of the completeness of item coverage, but also of its comprehensiveness, clarity, and readability is crucial. Asking patients about their general well-being, for example, might be too susceptible for different interpretations for reliable assessment of IBD disease activity. 8 Patients might also experience difficulties in understanding of extraintestinal manifestations, in interpretation of liquid or loose stools because they lack standardization, and in examination of the presence of an abdominal mass. Furthermore, pain measurement on a 4-point scale, for example, might be less suitable than on a visual analog scale, because response options need to offer a clear distinction between choices and should measure relevant nuances. The input of patients is especially important when PROMs are used to "value" health systems or interventions. However, patient-input during development was only carried out in 2 articles (patient-HBI and patient-SCCAI). 16, 17 In addition, 4 of the reviewed PROMs comprise of 1 single question on current disease activity. Because IBD disease activity is thought to manifest with a wide variety of symptoms, it could be discussed if a PROM consisting of 1 single global question captures all aspects of the complex process of disease activity. However, these single-item PROMs show comparable accuracy relative to the conventional clinical indices as the multi-item PROMs.
For a PROM measuring disease activity, validation relative to the golden standard, which is endoscopy for IBD activity, is important. Only 6 PROMs were validated relative to endoscopy and showed moderate accuracy for detection of mucosal inflammation in patients with UC and low accuracy in patients with CD (patients' global assessment, patient assessment of disease-activity, mHI-CD, mHI-UC, PRO2, and 6-point Mayo score). 11, 15, 19, 20 Because the development and validation of a new comprehensive PROM might take several years, many PROMs were derived or modified from existing clinical activity scores and validated relative to the original scores, and not to endoscopy. The mHI-UC and mHI-CD were newly developed based on correlation coefficients between individual questions from different available clinical activity scores with the partial Mayo score and HBI, respectively. The likelihood of establishing a PROM that reflects mucosal inflammation with a high accuracy may, however, increase when the selection of individual questions is driven by the correlation of these questions with endoscopic findings. For UC, for instance, rectal bleeding and to a lesser extent stool frequency were found to be essential in a UC-PROM. 20, 27 Nevertheless, it remains challenging to develop an accurate PROM because 20% of patients with UC in clinical remission still have endoscopic disease activity, whereas endoscopic healing is not always accompanied by normalization of stool frequency. 28, 29 For patients with CD, even up to 50% of patients in clinical remission still have mucosal inflammation. 30 The best patient-reported disease activity measure for a given situation may depend on research or clinical goals. For serial monitoring of disease activity in the context of tight control, high accuracy of a PROM compared with endoscopy is crucial. Specifically, such a disease activity index should have a high sensitivity, even if at the cost of false-positive results. In addition, ease of administration, short recall period, and good reliability and responsiveness to changes in disease activity are important for use in clinical practice. In this regard, the mHI-UC shows adequate measurement properties for assessing disease activity in patients with UC. 19, 20 For patients with CD, no PROM that accurately reflects endoscopic disease activity is available. For registration of a patients' perspective on disease activity at fixed time-points or over a certain period, use of the singleitem MIBDI, asking patients about their disease activity over the past 6 months, could be convenient. In clinical trials, however, a PROM that is consistent with guidance from the FDA might be first choice. However, none of the reviewed PROMs meet all the FDA criteria.
In this review we provide an overview of the available PROMs for IBD disease activity assessment. None of the available PROMs meet all the criteria for PROM development as recommended by the FDA. For most PROMs, information on their correlation with endoscopy is lacking and their utility to predict mucosal inflammation remains therefore unclear. The few articles that reported on criterion validity showed low to moderate accuracy in identifying patients with IBD at risk for active disease. In addition, only a minority of PROMs reported patient input during its development, which is crucial because PROMs are aimed at capturing patients' perspectives. With an increasing demand for use of PROMs in routine practice, clinical trials, telemedicine systems, and value-based health care programs, there is an urgent need for data regarding the content and criterion validity of the available PROMs. 
Supplementary Material
